Coya Therapeutics (COYA) Operating Margin (2023 - 2026)
Coya Therapeutics' (COYA) quarterly Operating Margin came in at 2891.13% in Q2 2026, up 102934.0% year-over-year from N/an in Q2 2025, and up 4.96% quarter-over-quarter from 3042.13% in Q1 2026.
Powered by 
Analysis
Coya Therapeutics (COYA) Operating Margin (2023 - 2026) Analysis & Trends
Coya Therapeutics has disclosed Operating Margin across 4 years of filings, most recently posting 2891.13% for Q2 2026.
- In Q2 2026, Operating Margin rose 102934.0% year-over-year to 2891.13%; the TTM figure through Jun 2026 stood at 288.7% (up 505359.0% YoY), while the FY2025 annual figure was 283.87%, up 20149.0% from the prior year.
- Operating Margin came in at 2891.13% for Q2 2026 at Coya Therapeutics, up from 3042.13% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 30.24% in Q4 2023 to a low of 209031.51% in Q4 2024.
- Average Operating Margin over 4 years is 22646.98%, with a median of 2934.01% recorded in 2025.
- Year-over-year, Operating Margin slumped 20906175 bps in 2024 and jumped 20887921 bps in 2025.
- Over 4 years, Operating Margin stood at 30.24% in 2023, then plunged by 691308 bps to 209031.51% in 2024, then surged by 100 bps to 152.3% in 2025, then tumbled by 1798 bps to 2891.13% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 2891.13% in Q2 2026, 3042.13% in Q1 2026, and 152.3% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | -25,380.93% |
| 10 | Coya Therapeutics | 107.20 Mn | 64.00 Mn | - | -2,891.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,891.13% |
| Mar 31, 2026 | -3,042.13% |
| Dec 31, 2025 | -152.30% |
| Sep 30, 2025 | -68.26% |
| Jun 30, 2025 | -3,920.47% |
| Mar 31, 2025 | -2,976.89% |
| Dec 31, 2024 | -209,031.51% |
| Jun 30, 2024 | -94.48% |
| Mar 31, 2024 | -4,322.84% |
| Dec 31, 2023 | 30.24% |